Diffuse large B-cell lymphoma (DLBCL) encompasses a diverse spectrum of aggressive B-cell lymphomas with remarkable genetic heterogeneity and myriad clinical presentations. Multiplatform genomic analyses of DLBCL have identified oncogenic drivers within genetic subtypes that allow for pathologic subclassification of tumors into discrete entities with shared immunophenotypic, genetic, and clinical features. Robust classification of lymphoid tumors establishes a foundation for precision medicine and enables the identification of novel therapeutic vulnerabilities within biologically homogeneous entities. Most cases of DLBCL involving the central nervous system (CNS), vitreous, and testis exhibit immunophenotypic features suggesting an activated B-cell (ABC) origin. Shared molecular features include frequent co-mutations of MYD88 (L265P) and CD79B and frequent genetic alterations promoting immune evasion, which are hallmarks of the MCD/C5/MYD88 genetic subtype of DLBCL. Clinically, these lymphomas primarily arise within anatomic sanctuary sites and have a predilection for remaining confined to extranodal sites and strong CNS tropism. Given the shared clinical and molecular features, the umbrella term primary large B-cell lymphoma of immune-privileged sites (IP-LBCL) was proposed. Other extranodal DLBCL involving breast, adrenal glands, and skin are often ABC DLBCL, but are more heterogeneous in their genomic profile and involve anatomic sites that are not considered immune privileged. In this review, we describe the overlapping clinical, pathologic, and molecular features of IP-LBCL and highlight important considerations for diagnosis, staging and treatment. We also discuss potential therapeutic vulnerabilities of IP-LBCL including sensitivity to inhibitors of Bruton's tyrosine kinase, immunomodulatory agents, and immunotherapy.
Skip Nav Destination
Review Article|
April 18, 2024
Primary Large B-cell Lymphomas of Immune-Privileged Sites
Mark Roschewski,
National Cancer Institute, NIH, Bethesda, Maryland, United States
* Corresponding Author; email: mark.roschewski@nih.gov
Search for other works by this author on:
James D. Phelan,
James D. Phelan
NIH, Bethesda, Maryland, United States
Search for other works by this author on:
Elaine S Jaffe
Elaine S Jaffe
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
Search for other works by this author on:
Blood blood.2023020911.
Article history
Submitted:
January 8, 2024
Revision Received:
March 22, 2024
Accepted:
April 2, 2024
Citation
Mark Roschewski, James D. Phelan, Elaine S Jaffe; Primary Large B-cell Lymphomas of Immune-Privileged Sites. Blood 2024; blood.2023020911. doi: https://doi.org/10.1182/blood.2023020911
Download citation file:
My Account
Sign InAdvertisement intended for health care professionals
1
Crossref
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal